Cargando…

Genomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values

BACKGROUND: New clinical genomic assays for lymphoid cancers allow for improved disease stratification and prognostication. At present, clinical implementation has been appropriately limited, owing to a paucity of evidence to support clinical and cost effectiveness. Understanding patients’ values fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa, Sarah, Regier, Dean A., Raymakers, Adam J. N., Pollard, Samantha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884583/ https://www.ncbi.nlm.nih.gov/pubmed/32875479 http://dx.doi.org/10.1007/s40271-020-00448-1

Ejemplares similares

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care
por: Raymakers, Adam J. N., et al.
Publicado: (2021)

Stakeholder Perspectives on Navigating Evidentiary and Decision Uncertainty in Precision Oncology
por: Pollard, Samantha, et al.
Publicado: (2022)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
por: Jain, Salvia, et al.
Publicado: (2011)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
por: Raymakers, A. J. N., et al.
Publicado: (2020)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication
por: Pollard, Samantha, et al.
Publicado: (2020)

Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
por: Ladbury, Colton, et al.
Publicado: (2022)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
por: Hallam, Simon
Publicado: (2018)

Development and early‐stage evaluation of a patient portal to enhance familial communication about hereditary cancer susceptibility testing: A patient‐driven approach
por: Pollard, Samantha, et al.
Publicado: (2023)

Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
por: Kunos, Charles A., et al.
Publicado: (2019)

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies
por: Armand, Philippe, et al.
Publicado: (2020)

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
por: Davids, Matthew S., et al.
Publicado: (2021)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
por: Pozzi, Samantha, et al.
Publicado: (2021)

Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin’s Lymphoma
por: Knecht, Hans, et al.
Publicado: (2013)

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2022)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Tertiary Lymphoid Structures in Colorectal Cancers and Their Prognostic Value
por: Trajkovski, Gjorgji, et al.
Publicado: (2018)

The prognostic value of the tertiary lymphoid structure in gastrointestinal cancers
por: Yu, Aoyang, et al.
Publicado: (2023)

Understanding cancer survivors’ reasons to medicate with cannabis: A qualitative study based on the theory of planned behavior
por: McTaggart‐Cowan, Helen, et al.
Publicado: (2020)

Toward the diagnosis of rare childhood genetic diseases: what do parents value most?
por: Pollard, Samantha, et al.
Publicado: (2021)

Salvage treatment of relapsed/refractory LCH
por: Seo, Jong Jin
Publicado: (2016)

Refractory relapsing polychondritis: challenges and solutions
por: Lekpa, Fernando Kemta, et al.
Publicado: (2018)

Novel Therapies for Relapsed and Refractory Neuroblastoma
por: Zage, Peter E.
Publicado: (2018)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma
por: Orlowski, Robert Z.
Publicado: (2018)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
por: MacEwan, Joanna P, et al.
Publicado: (2021)

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
por: Chung, Woonbok, et al.
Publicado: (2019)

Aleukemic extramedullary T lymphoid/myeloid bilineage hematopoietic and lymphoid malignancy with progression to bilineage leukemia at relapse: A case report
por: Wu, Mengyao, et al.
Publicado: (2017)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
por: Chiapponi, Costanza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l8m6jac1d90gnunqnhgidbb7sr